Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
ADVENT Trial Long Term Outcomes Evaluating Atrial Fibrillation Progression Study
NCT06526546 · View on ClinicalTrials.gov ↗
Study Summary
The (ADVENT LTO) is an observational, non-significant risk study to assess the progression of atrial fibrillation in subjects who received ablation treatment with either the FARAPULSE Pulsed Field Ablation System or thermal ablation in the ADVENT Trial.
Conditions Studied
Study Locations (20)
California
- Mills Peninsula Health Services — Burlingame
- Scripps Memorial Hospital — La Jolla
- University of California, San Francisco — San Francisco
Pennsylvania
- Doylestown Hospital — Doylestown
- Presbyterian University of Pennsylvania Medical Center — Philadelphia
- Pinnacle Health at Harrisburg Hospital — Wormleysburg
Massachusetts
- Massachusetts General Hospital (MGH) — Boston
- Beth Israel Deaconess Medical Center — Boston
New York
- Mount Sinai, Icahn School of Medicine — New York
- Northwell Health — New York
Alabama
- Grandview Medical Center — Birmingham
Arizona
- Banner University Medical Center Phoenix — Phoenix
District of Columbia
- Washington Hospital Center — Washington D.C.
Georgia
- Emory University Hospital — Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 364 participants |
| Start Date | 2024-10-31 |
| Est. Completion | 2025-12-08 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06526546
The ClinicalTrials.gov registry entry for NCT06526546 describes a study currently listed as completed. It is categorized as an unspecified phase, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 364 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boston Scientific Corporation, which has 120 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Paroxysmal Atrial Fibrillation appearing as the primary indexed condition, and to 0 interventions. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT06526546 reports 20 study locations spanning 14 distinct geographic areas — top geographies include California, Pennsylvania, Massachusetts. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT06526546 about?
NCT06526546 is a clinical study titled "ADVENT Trial Long Term Outcomes Evaluating Atrial Fibrillation Progression Study". The (ADVENT LTO) is an observational, non-significant risk study to assess the progression of atrial fibrillation in subjects who received ablation treatment with either the FARAPULSE Pulsed Field Ablation System or thermal ablation in the ADVENT Trial.
What is the current status of trial NCT06526546?
This trial is currently completed. The enrollment target is 364 participants. The study started on 2024-10-31. Estimated completion is 2025-12-08.
What conditions does trial NCT06526546 study?
This clinical trial studies the following conditions: Paroxysmal Atrial Fibrillation. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
Who is sponsoring clinical trial NCT06526546?
This trial is sponsored by Boston Scientific Corporation, which has 120 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT06526546 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, District of Columbia, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.